These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11355325)

  • 21. Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
    Idelevich E; Man S; Lavrenkov K; Gluzman A; Geffen DB; Shani A
    J Chemother; 2004 Oct; 16(5):487-90. PubMed ID: 15565917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
    Lin PC; Chen WS; Chao TC; Yang SH; Tiu CM; Liu JH
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):351-6. PubMed ID: 17111120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
    Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience.
    Wang WS; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Yen CC; Fan FS; Hsieh RK
    Jpn J Clin Oncol; 1998 Jan; 28(1):16-9. PubMed ID: 9491136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
    Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
    Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
    Kouroussis C; Souglakos J; Kakolyris S; Mavroudis D; Malamos N; Kalbakis K; Androulakis N; Agelaki A; Vardakis N; Samonis G; Georgoulias V
    Oncology; 2001; 61(1):36-41. PubMed ID: 11474246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
    Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation.
    Schöber C; Köhne-Wömpner CH; Schmoll HJ; Stahl M; Wilke HJ; Poliwoda H
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):136-40. PubMed ID: 1557639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
    Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
    J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
    Machover D; Grison X; Goldschmidt E; Zittoun J; Lotz JP; Metzger G; Richaud J; Hannoun L; Marquet J; Guillot T
    J Natl Cancer Inst; 1992 Mar; 84(5):321-7. PubMed ID: 1738182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
    Vincent M; Ho C; Tomiak A; Winquist E; Whiston F; Stitt L
    Clin Colorectal Cancer; 2002 Aug; 2(2):111-8. PubMed ID: 12453326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels.
    Ishizuka D; Shirai Y; Sakai Y; Hatakeyama K
    Int J Colorectal Dis; 2001 Feb; 16(1):32-7. PubMed ID: 11317695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.